Pricing Log in Create free account

Grace Therapeutics, Inc. (GRCE) vs 4D pharma PLC Sponsored ADR (LBPS)

Grace Therapeutics, Inc. and 4D pharma PLC Sponsored ADR are both Biotechnology companies. Grace Therapeutics, Inc. is the larger, with a market value of $41.0M against $37.2M — 1.1× the size. Grace Therapeutics, Inc. has the higher net margin (0.00% vs −2,010.9%) and the lower return on invested capital (−43.4% vs 0.00%). Across the 14 metrics below, Grace Therapeutics, Inc. leads on 9 and 4D pharma PLC Sponsored ADR on 5.

Valuation

Metric GRCE LBPS Biotechnology median
P/E n/m n/m 8.50
P/S 163.45 211.23 9.71
P/B 0.68 9.49 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m — 0.64
EV/Sales 108.68 — 9.21
Earnings yield (62.43%) (40.76%) (33.15%)
Free cash flow yield (31.27%) (30.32%) (25.50%)

Profitability

Metric GRCE LBPS Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (2,010.89%) 0.00%
Free cash flow margin 0.00% (3,283.80%) 0.00%
Return on equity (36.19%) (155.83%) (56.36%)
Return on assets (33.74%) (77.95%) (48.04%)
Return on invested capital (43.36%) 0.00% 0.00%

Growth

Metric GRCE LBPS Biotechnology median
Revenue growth (TTM) 1,286.81% — 6.02%
EPS growth (last fiscal year) 40.51% 35.04% 30.26%
Revenue growth, 5-year CAGR (22.91%) 21.70% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GRCE LBPS Biotechnology median
Debt to equity 0.00 0.43 0.00
Current ratio 11.47 5.21 4.72
Net debt to EBITDA 1.53 0.23 0.96

Dividend

Metric GRCE LBPS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GRCE LBPS Biotechnology median
Market cap 41.02m 37.19m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack